Conditional cell ablation by tight control of caspase-3 dimerization in transgenic mice

Nature Biotechnology

Volumn 20, Issue 12, 2002, Pages 1234-1239

  Mallet, Vincent O ^a   Mitchell, Claudia ^a   Guidotti, Jacques Emmanuel ^a   Jaffray, Patrick ^b   Fabre, Monique ^c   Spencer, David ^d   Arnoult, Damien ^e   Kahn, Axel ^a   Gilgenkrantz, Helene ^a  

^a INSTITUT COCHIN   (France)

^b Cochin Hospital ^*  (France)

^c BICÊTRE HOSPITAL   (France)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION; CELLS; CHEMICAL ACTIVATION; DIMERIZATION; PATHOLOGY; TISSUE;

HUMAN DISORDERS;

GENETIC ENGINEERING;

CASPASE 3; CYTOCHROME C; PREALBUMIN; RNA; AP20187; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; DRUG DERIVATIVE; HYBRID PROTEIN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; CELL PROLIFERATION; CELL REGENERATION; CELL TYPE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; LIVER FAILURE; LIVER INJURY; LIVER REGENERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CELL; MACROMOLECULE; METABOLISM; PATIENT MONITORING; PHYSIOLOGY; REFERENCE VALUE;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASES; CELL LINE; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; INJECTIONS, INTRAPERITONEAL; LIVER REGENERATION; MACROMOLECULAR SUBSTANCES; MICE; MICE, TRANSGENIC; MONITORING, INTRAOPERATIVE; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; TACROLIMUS;

EID: 0036904978     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt762     Document Type: Article

References (39)

1. Galle, P. R. et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223-1230 (1995).
2. Nanji, A. A. Apoptosis and alcoholic liver disease. Semin. Liver. Dis. 18, 187-190 (1998).
3. Fox, C. K., Furtwaengler, A., Nepomuceno, R. R., Martinez, O. M. & Krams, S. M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 21, 272-279 (2001).
4. Strand, S. et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat. Med. 4, 588-593 (1998).
5. Rudiger, H. A. & Clavien, P. A. Tumor necrosis factor-α, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology 122, 202-210 (2002).
6. Patel, T., Roberts, L. R., Jones, B. A. & Gores, G. J. Dysregulation of apoptosis as a mechanism of liver disease: An overview. Semin. Liver. Dis. 18, 105-114 (1998).
7. Lee, W. M. Acute liver failure. N. Engl. J. Med. 329, 1862-1872 (1993).
8. Fingerote, R. J. & Bain, V. G. Fulminant hepatic failure. Am. J. Gastroenterol. 88, 1000-1010 (1993).
9. Caraceni, P. & Van Thiel, D. H. Acute liver failure. Lancet 345, 163-169 (1995).
10. Fausto, N. Liver regeneration. J. Hepatol. 32, 19-31 (2000).
11. Kosai, K., Matsumoto, K., Funakoshi, H. & Nakamura, T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 30, 151-159 (1999).
12. Hecht, N. et al. Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol. Ther. 3, 683-687 (2001).
13. Kobayashi, N. et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 287, 1258-1262 (2000).
14. Newsome, P. N., Plevris, J. N., Nelson, L. J. & Hayes, P. C. Animal models of fulminant hepatic failure: A critical evaluation. Liver Transpl. 6, 21-31 (2000).
15. Palmiter, R. D. et al. Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell 50, 435-443 (1987).
16. Behringer, R. R., Mathews, L. S., Palmiter, R. D. & Brinster, R. L. Dwarf mice produced by genetic ablation of growth hormone-expressing cells. Genes Dev. 2, 453-461 (1988).
17. Braun, K. M., Degen, J. L. & Sandgren, E. P. Hepatocyte transplantation in a model of toxin-induced liver disease: Variable therapeutic effect during replacement of damaged parenchyma by donor cells. Nat. Med. 6, 320-326 (2000).
18. Matthews, T. & Boehme, R. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10, S490-S494 (1988).
19. Culver, K. W. et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552 (1992).
20. Saito, M. et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 19, 746-750 (2001).
21. Kobayashi, K. et al. Immunotoxin-mediated conditional disruption of specific neurons in transgenic mice. Proc. Natl. Acad. Sci. USA 92, 1132-1136 (1995).
22. Collier, R. J. in ADP-Ribosylating Toxins and G Proteins: Insights into Signal Transduction (eds. Moss, J. & Vaughan, M.) 3-19 (American Society for Microbiology, Washington, DC, 1990).
23. Fan, L., Freeman, K. W., Khan, T., Pham, E. & Spencer, D. M. Improved artificial death switches based on caspases and FADD. Hum. Gene Ther. 10, 2273-2285 (1999).
24. Yan, C., Costa, R. H., Darnell, J. E. Jr., Chen, J. D. & Van Dyke, T. A. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J. 9, 869-878 (1990).
25. Clackson, T. et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. USA 95, 10437-10442 (1998).
26. Krajewska, M. et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res. 57, 1605-1613 (1997).
27. Cheng, E. H. et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278, 1966-1968 (1997).
28. Woo, M. et al. In vivo evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes. J. Immunol. 163, 4909-4916 (1999).
29. Slee, E. A., Keogh, S. A. & Martin, S. J. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: A potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ. 7, 556-565 (2000).
30. Jones, R. A. et al. Fas-mediated apoptosis in mouse hepatocytes involves the processing and activation of caspases. Hepatology 27, 1632-1642 (1998).
31. Zheng, T. S. et al. Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc. Natl. Acad. Sci. USA 95, 13618-13623 (1998).
32. Janin, A. et al. CD95 engagement induces disseminated endothelial cell apoptosis in vivo: Immunopathologic implications. Blood 99, 2940-2947 (2002).
33. Lee, P. et al. Conditional lineage ablation to model human diseases. Proc. Natl. Acad. Sci. USA 95, 11371-11376 (1998).
34. Xie, X. et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 61, 6795-6804 (2001).
35. Mercer, D. F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7, 927-933 (2001).
36. Yoon, J.W. & Jun, H.-S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann. NY Acad. Sci. 928, 200-211 (2001).
37. Narula, J. et al. Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 96, 8144-8149 (1999).
38. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299 (1979).
39. Gross, A. et al. Caspase-cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274, 1156-1163 (1999).